早期胰岛素强化联合不同治疗方案对新诊断T2DM的效果(1)
摘要：目的 探究早期胰岛素强化治疗后给予不同治疗方案对新诊断2型糖尿病(T2DM)患者的治疗效果。方法 选择我院2019年3～12月新诊断62例T2DM患者作为研究对象，按照随机数字表法分为基础胰岛素(Bal)组21例、预混胰岛素(Prx)组21例、磺脲类促胰岛素分泌剂(Sus)组20例，行早期胰岛素强化治疗后按照上述三种不同方案进行治疗，比较三组空腹血糖(FPC)、空腹C肽水平及胰岛β细胞功能(HOMA-β)、胰岛素抵抗指数(HOMA-IR)。结果 强化治疗前，三组FPC、空腹C肽水平比较，差异无统计学意义(P>0.05);治疗后，Sus组FPC水平低于Bal组、Prx组，空腹C肽水平高于Bal组、Prx组，差异有统计学意义(P<0.05);Sus组HOMA-β高于Bal组、Prx组，HOMA-IR低于Bal组、Prx组，差异有统计学意义(P<0.05)。结论 新诊断T2DM患者在胰岛素强化治疗后使用格列齐特缓释片等磺脲类促胰岛素分泌剂进行后续治疗可以更有效地改善患者的血糖水平和胰岛β细胞功能。
关键词：胰岛素强化;预混胰岛素;基础胰岛素;磺脲类促胰岛素分泌剂;新诊断2型糖尿病
Abstract：Objective To explore the therapeutic effects of different treatments after early intensive insulin therapy on newly diagnosed type 2 diabetes (T2DM) patients.Methods 62 newly diagnosed T2DM patients in our hospital from March to December 2019 were selected as the research objects. According to the random number table， they were divided into 21 cases in the basal insulin (Bal) group， 21 cases in the premixed insulin (Prx) group， and sulfonylureas. 20 patients in the insulin secretion agent (Sus) group were treated with the above three different regimens after early intensive insulin therapy. The three groups were compared with fasting blood glucose (FPC)， fasting C-peptide levels， islet β-cell function (HOMA-β)， and insulin resistance index (HOMA-IR).Results Before intensive treatment， there was no significant difference in FPC and fasting C-peptide levels among the three groups (P>0.05); after treatment， FPC levels in Sus group were lower than Bal and Prx groups， and fasting C-peptide levels were higher than Bal and Prx Group， the difference was statistically significant (P<0.05); Sus group HOMA-β was higher than Bal group and Prx group， HOMA-IR was lower than Bal group， Prx group， the difference was statistically significant (P<0.05).Conclusion The use of sulfonylurea insulin secretagogues such as Gliclazide sustained-release tablets for subsequent treatment of newly diagnosed T2DM patients after intensive insulin therapy could more effectively improve the patient's blood glucose level and pancreatic β-cell function.
Key words：Insulin enhancement;Premixed insulin;Basal insulin;Sulfonylurea insulin secretagogue;Newly diagnosed type 2 diabetes
2型糖尿病(diagnosed type 2 diabetes，T2MD)是臨床上糖尿病的主要类型，其确切发病原因尚未明确，但当前公认的是胰岛素抵抗和胰岛β细胞功能损伤是诱发该病的重要原因[1]。研究显示[2]，胰岛素强化治疗后采取注射胰岛素、口服药物等措施进行后续治疗可有效控制患者血糖，缓解病情。临床上可用于后续治疗的药物有很多，如甘精胰岛素、门冬胰岛素等，但对于何种治疗方案可取得更佳的治疗效果的研究较少。为探究早期胰岛素强化治疗后给予不同治疗方案对新诊断T2DM患者的治疗效果，本研究选取我院2019年3～12月新诊断T2DM患者62例展开分析，现报道如下。, 百拇医药(马晓云)
关键词：胰岛素强化;预混胰岛素;基础胰岛素;磺脲类促胰岛素分泌剂;新诊断2型糖尿病
Abstract：Objective To explore the therapeutic effects of different treatments after early intensive insulin therapy on newly diagnosed type 2 diabetes (T2DM) patients.Methods 62 newly diagnosed T2DM patients in our hospital from March to December 2019 were selected as the research objects. According to the random number table， they were divided into 21 cases in the basal insulin (Bal) group， 21 cases in the premixed insulin (Prx) group， and sulfonylureas. 20 patients in the insulin secretion agent (Sus) group were treated with the above three different regimens after early intensive insulin therapy. The three groups were compared with fasting blood glucose (FPC)， fasting C-peptide levels， islet β-cell function (HOMA-β)， and insulin resistance index (HOMA-IR).Results Before intensive treatment， there was no significant difference in FPC and fasting C-peptide levels among the three groups (P>0.05); after treatment， FPC levels in Sus group were lower than Bal and Prx groups， and fasting C-peptide levels were higher than Bal and Prx Group， the difference was statistically significant (P<0.05); Sus group HOMA-β was higher than Bal group and Prx group， HOMA-IR was lower than Bal group， Prx group， the difference was statistically significant (P<0.05).Conclusion The use of sulfonylurea insulin secretagogues such as Gliclazide sustained-release tablets for subsequent treatment of newly diagnosed T2DM patients after intensive insulin therapy could more effectively improve the patient's blood glucose level and pancreatic β-cell function.
Key words：Insulin enhancement;Premixed insulin;Basal insulin;Sulfonylurea insulin secretagogue;Newly diagnosed type 2 diabetes
2型糖尿病(diagnosed type 2 diabetes，T2MD)是臨床上糖尿病的主要类型，其确切发病原因尚未明确，但当前公认的是胰岛素抵抗和胰岛β细胞功能损伤是诱发该病的重要原因[1]。研究显示[2]，胰岛素强化治疗后采取注射胰岛素、口服药物等措施进行后续治疗可有效控制患者血糖，缓解病情。临床上可用于后续治疗的药物有很多，如甘精胰岛素、门冬胰岛素等，但对于何种治疗方案可取得更佳的治疗效果的研究较少。为探究早期胰岛素强化治疗后给予不同治疗方案对新诊断T2DM患者的治疗效果，本研究选取我院2019年3～12月新诊断T2DM患者62例展开分析，现报道如下。, 百拇医药(马晓云)